FrancophonIA/ELRC3.0 huggingface dataset:
English: For the full list of restrictions with Abraxane, see the package leaflet.
Estonian: Abraxane piirangute täielik loetelu on pakendi infolehel.
English: In Abraxane, unlike conventional paclitaxel-containing medicines, the paclitaxel is attached to a human protein called albumin in tiny particles known as ‘nanoparticles'.
Estonian: Erinevalt tavapärastest paklitakseeli sisaldavatest ravimitest on Abraxanes paklitakseel seotud inimvalgu albumiiniga ja moodustab väga peene, nanoosakestest koosneva pulbri.
English: For non-small cell lung cancer, the Abraxane-carboplatin combination was compared with a combination of a conventional paclitaxel-containing medicine and carboplatin in 1,052 patients.
Estonian: Abraxane ja karboplatiini kombinatsiooni toimet mitteväikerakk-kopsuvähile uuriti võrreldes tavapärase paklitakseeli sisaldava ravimi ja karboplatiini kombinatsiooni toimega 1052 patsiendil.
English: How does Abraxane work?
Estonian: Kuidas Abraxane toimib?
English: Abraxane paclitaxel
Estonian: Abraxane paklitakseel
English: What benefit has Abraxane shown during the studies?
Estonian: Milles seisneb uuringute põhjal Abraxane kasulikkus?
English: • metastatic adenocarcinoma of the pancreas, as a first treatment in combination with another cancer medicine, gemcitabine.
Estonian: • Pankrease (kõhunäärme) metastaatilise adenokartsinoomi esmaravimina koos teise vähiravimi gemtsitabiiniga.
English: The active substance in Abraxane, paclitaxel, belongs to the group of cancer medicines known as the ‘taxanes'.
Estonian: Abraxane toimeaine paklitakseel kuulub vähiravimite taksaanide rühma.
English: In metastatic breast cancer Abraxane is given on its own every three weeks.
Estonian: Metastaatilise rinnavähi korral manustatakse Abraxanet ainuravimina iga kolme nädala tagant.
English: For the full list of all side effects reported with Abraxane, see the package leaflet.
Estonian: Abraxane kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: In metastatic adenocarcinoma of the pancreas Abraxane is given in 4-week treatment cycles.
Estonian: Pankrease metastaatilise adenokartsinoomi korral manustatakse Abraxanet 4-nädalaste ravitsüklitena.
English: How is Abraxane used?
Estonian: Kuidas Abraxanet kasutatakse?
English: What is Abraxane used for?
Estonian: Milleks Abraxanet kasutatakse?
English: How has Abraxane been studied?
Estonian: Kuidas Abraxanet uuriti?
English: In metastatic adenocarcinoma of the pancreas, Abraxane was shown to improve overall survival.
Estonian: Pankrease metastaatilise adenokartsinoomiga patsientidel suurendas Abraxane üldist elulemust.
English: In contrast, Abraxane was more effective than conventional paclitaxel-containing medicines in patients who had taken other treatments for metastatic breast cancer before.
Estonian: Seevastu oli Abraxane patsientidel, kellel oli metastaatilist rinnavähki muude ravimitega varem ravitud, efektiivsem kui tavapärased paklitakseeli sisaldavad ravimid.
English: Treatment may be repeated for up to five consecutive days.
Estonian: Ravi tohib korrata kuni 5 järjestikusel päeval.
English: ATCvet code: QA04AD90
Estonian: ATCvet kood: QA04AD90
English: No data have been presented on overdoses in adult cats.
Estonian: Andmeid üleannustamise kohta täiskasvanud kassidel ei ole esitatud.
English: Maropitant is effective against vomiting.
Estonian: Maropitant on oksendamise vastu efektiivne.
English: For administration by subcutaneous injection, see also “special precautions for use in animals” (section 4.5).
Estonian: Subkutaanse manustamise kohta vt ka „Ettevaatusabinõud kasutamisel loomadel“ (lõik 4.5).
English: Vomiting is a complex process coordinated centrally by the emetic centre.
Estonian: Oksendamine on keerukas protsess, mida tsentraalselt koordineerib oksekeskus.
English: • For the treatment of vomiting, in combination with other supportive measures.
Estonian: • Oksendamise raviks koos teiste toetavate meetmetega.
English: In cats, moderate to severe response to injection is very commonly observed (in approximately one third of cats).
Estonian: Kassidel täheldati mõõdukat kuni tugevat reaktsiooni süstimisele väga sageli (ligikaudu ühel kolmandikul kassidel).
English: • For the prevention of perioperative nausea and vomiting and improvement in recovery from general anaesthesia after use of the μ-opiate receptor agonist morphine.
Estonian: • Perioperatiivse iivelduse ja oksendamise ennetamiseks ja üldanesteesiast taastumise parandamiseks μ-opiaadi retseptori agonisti morfiini kasutamise järel.
English: This centre consists of several brainstem nuclei (area postrema, nucleus tractus solitarius, dorsal motor nucleus of the vagus) that receive and integrate sensory stimuli from central and peripheral sources and chemical stimuli from the circulation and the cerebro-spinal fluid.
Estonian: Oksekeskus koosneb mitmest ajutüve tuumast (area postrema, nucleus tractus solitarius, n. vagus'e dorsaalne motoorne tuum), mis võtavad vastu ja integreerivad tsentraalsetest ja perifeersetest allikatest pärinevaid stiimuleid ning vereringest ja liikvorist pärinevaid keemilisi stiimuleid.
English: MANUFACTURER'S BATCH NUMBER Lot:
Estonian: TOOTJAPOOLNE PARTII NUMBER Partii nr:
English: 10 DATE OF REVISION OF THE TEXT <{MM/YYYY}>
Estonian: TEKSTI LÄBIVAATAMISE KUUPÄEV <{KK/AAAA}>
English: Use only according to the benefit-risk assessment by the responsible veterinarian, because conclusive reproductive toxicity studies have not been conducted in any animal species.
Estonian: Kasutada ainult vastavalt vastutava loomaarsti tehtud kasu-riski suhte hinnangule, sest ühelgi loomaliigil ei ole tehtud ammendavaid reproduktiivtoksilisuse uuringuid.
English: The elimination t1/2 following intravenous dosing was approximately 5.8 h.
Estonian: Eliminatsiooni t1/2 oli pärast intravenoosset manustamist ligikaudu 5,8 h.
English: Excipients: Benzyl alcohol (E1519)
Estonian: Abiained: Bensüülalkohol (E1519)
English: In laboratory studies, maropitant has been shown to be a potential eye irritant.
Estonian: Laboriuuringud on tõendatud, et maropitant võib ärritada silmi.
English: The elimination t1/2 following intravenous dosing was approximately 4.9 h. There appears to be an age-related effect on the pharmacokinetics of maropitant in cats with kittens having higher clearance than adults.
Estonian: Eliminatsiooni t1/2 oli pärast intravenoosset manustamist ligikaudu 4,9 h. Kassidel näib maropitandi farmakokineetika sõltuvat vanusest, kusjuures kassipoegadel on kliirens suurem kui täiskasvanud kassidel.
English: MARKETING AUTHORISATION NUMBER(S) EU/2/17/211/001-004 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 19/06/2017
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE / MÜÜGILOA UUENDAMISE KUUPÄEV Esmase müügiloa väljastamise kuupäev: 19/06/2017
English: Therefore, it is recommended to administer the veterinary medicinal product prior to administration of the chemotherapeutic agent.
Estonian: Seega soovitatakse seda veterinaarravimit kasutada enne keemiaravi manustamist.
English: 11.1 mg For the full list of excipients, see section 6.1.
Estonian: 11,1 mg Abiainete täielik loetelu on esitatud lõigus 6.1.
English: Manufacturer responsible for batch release: Produlab Pharma B.V.
Estonian: Partii vabastamise eest vastutav tootja: Produlab Pharma B.V.
English: Pack sizes of 1 vial of 10 ml, 20 ml, 25 ml or 50 ml.
Estonian: Pakendis on üks 10 ml, 20 ml, 25 ml või 50 ml viaal.
English: Marketing authorisation holder: Le Vet Beheer B.V.
Estonian: Müügiloa hoidja: Le Vet Beheer B.V.
English: In very rare cases, anaphylactic type reactions (allergic oedema, urticaria, erythema, collapse, dyspnoea, pale mucous membranes) may occur.
Estonian: Väga harvadel juhtudel võivad tekkida anafülaktilised reaktsioonid (allergiline turse, urtikaaria, erüteem, sünkoop, düspnoe, limaskestade kahvatus).
English: Comment: Given the small vial size(s), would it not be preferable to replace these by “SC, IV"
Estonian: Kommentaar: Viaali väiksuse tõttu võib olla vaja manustamisviise märkida kui „SC, IV“
English: Maropitant is a neurokinin 1 (NK1) receptor antagonist, which acts by inhibiting the binding of substance P, a neuropeptide of the tachykinin family.
Estonian: Maropitant on neurokiniin 1 (NK1) retseptori antagonist, mis toimib tahhükiniinide rühma kuuluva neuropeptiidi substants P seondumise inhibeerimise kaudu.
English: PHARMACOLOGICAL PROPERTIES Pharmacotherapeutic group: Antiemetics.
Estonian: FARMAKOLOOGILISED OMADUSED Farmakoterapeutiline rühm: oksendamisvastased ained.
English: In case of accidental self-injection seek medical advice immediately and show the package leaflet or the label to the physician.
Estonian: Juhuslikul süstimisel iseendale pöörduda viivitamatult arsti poole ja näidata pakendi infolehte või pakendi etiketti.
English: Good veterinary practice indicates that antiemetics should be used in conjunction with other veterinary and supportive measures such as dietary control and fluid replacement therapy while addressing the underlying causes of the vomiting.
Estonian: Hea veterinaartava kohaselt kasutatakse oksendamisvastaseid ravimeid koos teiste veterinaarsete ja toetavate meetmetega, näiteks reguleeritud dieedi ja vedeliku asendusraviga, lahendades samal ajal ka oksendamise põhjust.
English: Prevomax must not be mixed with other veterinary medicinal products in the same syringe as its compatibility with other products has not been tested.
Estonian: Prevomaxi ei tohi samas süstlas segada teiste veterinaarravimitega, sest selle sobivust teiste ravimitega ei ole uuritud.
English: Due to the frequent occurrence of transient pain during subcutaneous injection, appropriate animal restraining measures may have to be applied.
Estonian: Arvestades subkutaanse süstega seotud mööduva valu sagedat esinemist, võib olla vaja loom asjakohaselt fikseerida.
English: For subcutaneous or intravenous use in dogs and cats.
Estonian: Subkutaanne või intravenoosne kasutus (koerad ja kassid).
English: Products such as Prevomax should be used in conjunction with other supportive measures such as dietary control and fluid replacement therapy, as recommended by your veterinary surgeon.
Estonian: Selliseid ravimeid nagu Prevomax peab kasutama koos teiste toetavate meetmetega, näiteks reguleeritud dieedi ja vedeliku asendusraviga, nagu on soovitanud veterinaararst.
English: In the case of accidental eye exposure, flush the eyes with plenty of water and seek medical attention.
Estonian: Ravimi juhuslikul sattumisel silma tuleb silmi loputada rohke veega ja pöörduda arsti poole.
English: The safety of maropitant has not been established in dogs less than 8 weeks of age, or in cats less than 16 weeks of age, or in pregnant or lactating dogs and cats.
Estonian: Maropitandi ohutus ei ole tõendatud alla 8-nädalastel koertel ega alla 16-nädalastel kassidel ning tiinetel või lakteerivatel koertel või kassidel.
English: By inhibiting the binding of substance P within the emetic centre, maropitant is effective against neural and humoral (central and peripheral) causes of vomiting.
Estonian: Oksekeskuses substants P seondumist inhibeerides on maropitant efektiivne oksendamise neuraalsete ja humoraalsete (tsentraalsete ja perifeersete) põhjuste korral.
English: During clinical studies maropitant plasma levels conferred efficacy from 1 hour after administration.
Estonian: Kliinilistes uuringutes saabus maropitandi efektiivne plasmakontsentratsioon 1 tund pärast manustamist.
English: As the pharmacokinetic variation is large and maropitant accumulates in the body after once daily repeated administration, lower doses than recommended might be sufficient in some individuals and when repeating the dose.
Estonian: Et farmakokineetiline varieeruvus on suur ja maropitant akumuleerub organismi ravimi korduval manustamisel üks kord ööpäevas, võib mõnel loomal korduva manustamise ajal olla piisav, kui kasutatakse soovitatust väiksemat annust.
English: In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products in the same syringe.
Estonian: Sobivusuuringute puudumise tõttu ei tohi seda veterinaarravimit samas süstlas teiste veterinaarravimitega segada.
English: For the major metabolite 10.4% of the maropitant dose was recovered in urine and 9.3% in faeces.
Estonian: Maropitandi annusest 10,4% tuvastati peamise metaboliidina uriinis ja 9,3% roojas.
English: Substance P is found in significant concentrations in the nuclei comprising the emetic centre and is considered the key neurotransmitter involved in vomiting.
Estonian: Oksekeskust moodustavates tuumades on substants P-d leitud olulistes kontsentratsioonides ning arvatakse, et see on peamine oksendamisprotsessis osalev neurotransmitter.
English: The bioavailability of maropitant after subcutaneous administration in dogs was 90.7%.
Estonian: Maropitandi biosaadavus subkutaansel manustamisel koertele oli 90,7%.
English: Shelf life after first opening the vial: 56 days.
Estonian: Kõlblikkusaeg pärast viaali esmast avamist: 56 päeva.
English: Specific pharmacovigilance requirements: The PSURs for Prevomax shall be submitted at the same frequency as for Cerenia (reference product).
Estonian: Prevomaxi kohta tuleb esitada ravimi perioodiline ohutusaruanne (PSUR) sama sagedusega kui Cerenia (võrdlusravimi) puhul.
English: Vomiting can be associated with serious, severely debilitating conditions and the cause should be investigated.
Estonian: Oksendamine võib olla seotud raskete, üldseisundit oluliselt halvendavate seisunditega ja seetõttu peab uurima oksendamise põhjuseid.
English: Maropitant is highly bound to plasma proteins and may compete with other highly bound drugs.
Estonian: Maropitant seondub suures ulatuses plasmavalkudega ja võib konkureerida teiste ravimitega, mis ulatuslikult seonduvad plasmavalkudega.
English: A variety of in vitro assays have demonstrated that maropitant binds selectively at the NK1 receptor with dose-dependent functional antagonism of substance P activity.
Estonian: Mitme in vitro analüüsiga on tõestatud, et maropitant seondub selektiivselt NK1-retseptoriga ja sellel on annussõltuv funktsionaalne antagonism substants P toime suhtes.
English: Shelf life after first opening the immediate packaging: 56 days.
Estonian: Kõlblikkusaeg pärast vahetu pakendi esmast avamist: 56 päeva.
English: The veterinary medicinal product should not be used concomitantly with Ca-channel antagonists as maropitant has affinity to Ca-channels.
Estonian: Veterinaarravimit ei tohi kasutada koos Ca-kanali antagonistidega, sest maropitant on Ca-kanalite suhtes afiinne.
English: Although maropitant has been demonstrated to be effective in both the treatment and prevention of emesis induced by chemotherapy, it was found more efficacious if used preventively.
Estonian: Maropitandi efektiivsus on tõestatud nii keemiaravist tingitud oksendamise raviks kui ka ennetamiseks, kuid ravimi efektiivsus oli ennetaval kasutamisel suurem.
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Glass vial
Estonian: MINIMAALSED ANDMED, MIS PEAVAD OLEMA VÄIKESEL VAHETUL SISEPAKENDIL
English: Do not use this veterinary medicinal product after the expiry date which is stated on the label of the vial after EXP.
Estonian: Ärge kasutage veterinaarravimit pärast kõlblikkusaega, mis on märgitud viaali etiketil pärast märget „Kõlblik kuni:“.
English: QUANTITY OF THE ACTIVE SUBSTANCE(S) 10 mg/ml
Estonian: TOIMEAINE(TE) KOGUS 10 mg/ml
English: The anti-emetic efficacy of maropitant against central and peripheral emetics was demonstrated in experimental studies including apomorphine, cisplatin and syrup of ipecac (dogs) and xylazine (cats).
Estonian: Maropitandi oksendamisvastane efektiivsus oksendamise tsentraalsete ja perifeersete põhjuste korral on tõestatud katseuuringutes, milles kasutati apomorfiini, tsisplatiini ning oksejuure (koertel) ja ksülasiini (kassidel) siirupit.
English: As maropitant is accumulated in the body during a 14 day treatment period due to metabolic saturation, careful monitoring of liver function and any adverse events should be implemented during long term treatment.
Estonian: Metaboolse küllastumise tõttu akumuleerub maropitant 14-päevase ravikuuri jooksul organismi, mistõttu tuleb pikaajalise ravi ajal hoolikalt jälgida maksafunktsiooni ja mis tahes kõrvalnähtude teket.
English: Maropitant undergoes cytochrome P450 (CYP) metabolism in the liver.
Estonian: Maropitant metaboliseerub maksas tsütokroomi P450 (CYP) süsteemi kaudu.
English: Maropitant is metabolised in the liver and therefore should be used with caution in dogs and cats with liver disease.
Estonian: Maropitant metaboliseerub maksas ja seega tuleb ravimit maksahaigusega koertel ja kassidel kasutada ettevaatlikult.
English: People with known hypersensitivity to maropitant should administer the veterinary medicinal product with caution.
Estonian: Ettevaatusabinõud veterinaarravimit loomale manustavale isikule Inimesed, kellel on tegemist teadaoleva ülitundlikkusega maropitandi suhtes, peavad veterinaarravimit manustama ettevaatusega.
English: The duration of effect is approximately 24 h and therefore treatment can be given the night before administration of an agent that may cause emesis e.g. chemotherapy.
Estonian: Toime püsib ligikaudu 24 tundi ja seega tohib ravimit manustada ka oksendamist põhjustava ravimi, näiteks keemiaravi manustamisele eelneval õhtul.
English: The bioavailability of maropitant after subcutaneous administration in cats was 91.3%.
Estonian: Maropitandi biosaadavus subkutaansel manustamisel kassidele oli 91,3%.
English: MANUFACTURER RESPONSIBLE FOR BATCH RELEASE Name and address of the manufacturer responsible for batch release Produlab Pharma B.V.
Estonian: RAVIMIPARTII VABASTAMISE EEST VASTUTAV TOOTJA Ravimipartii vabastamise eest vastutava tootja nimi ja aadress Produlab Pharma B.V.
English: The responsible veterinarian should make a benefit-risk assessment before using the veterinary medicinal product in dogs less than 8 weeks of age, or in cats less than 16 weeks of age, or in pregnant or lactating bitches and cats.
Estonian: Vastutav loomaarst peab enne selle veterinaarravimi kasutamist alla 8-nädalastel koertel või alla 16-nädalastel kassidel ning tiinetel või lakteerivatel koertel või kassidel hindama kasulikkust ja riski.
English: The efficacy of maropitant in reduction of nausea in cats was demonstrated in studies using a model (xylazine-induced nausea).
Estonian: Maropitandi efektiivsus iivelduse vähendamisel kassidel on tõendatud uuringutega, milles kasutati mudelit (ksülasiini indutseeritud iiveldus).
English: Following a single intravenous dose at 1 mg/kg the initial plasma concentration was 363 ng/ml.
Estonian: Ühekordse intravenoosse annuse 1 mg/kg manustamise järel oli algne plasmakontsentratsioon 363 ng/ml.
English: To prevent vomiting, the veterinary medicinal product solution for injection should be administered more than 1 hour in advance.
Estonian: Oksendamise ennetamiseks tuleb veterinaarravimi süstelahust manustada rohkem kui 1 tund enne soovitud toime algust.
English: Injecting the product at refrigerated temperature may reduce pain at injection.
Estonian: Süstekoha valu võib vähendada see, kui süstitav ravim on külmikutemperatuuril.
English: Prevomax should be used with caution in animals suffering from or with predisposition for heart diseases.
Estonian: Prevomaxi peab südamehaigustega või nende eelsoodumusega loomadel kasutama ettevaatlikult.
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals, including isolated reports treated).
Estonian: Kõrvaltoimete esinemissagedus on defineeritud järgnevalt: - Väga sage (kõrvaltoime(d) ilmnes(id) rohkem kui 1-l loomal 10-st ravitud loomast) - Sage (rohkem kui 1-l, kuid vähem kui 10-l loomal 100-st ravitud loomast) - Aeg-ajalt (rohkem kui 1-l, kuid vähem kui 10-l loomal 1000-st ravitud loomast) - Harv (rohkem kui 1-l, kuid vähem kui 10-l loomal 10000-st ravitud loomast) - Väga harv (vähem kui 1-l loomal 10000-st ravitud loomast, kaasaarvatud üksikjuhud).
English: The volume of distribution at steady-state (Vss) was 2.3 l/kg and systemic clearance was 0.51 l/h/kg.
Estonian: Tasakaaluseisundis oli jaotusruumala (Vss) 2,3 l/kg ja süsteemne kliirens 0,51 l/h/kg.
English: The veterinary medicinal product should be used with caution in animals suffering from or with predisposition for cardiac diseases as maropitant has affinity to Ca- and K-ion channels.
Estonian: Veterinaarravimit peab südamehaigustega või nende eelsoodumusega loomadel kasutama ettevaatlikult, sest maropitant on Ca- ja K-ioonikanalite suhtes afiinne.
English: Following a single intravenous dose at 1 mg/kg the initial plasma concentration was 1040 ng/ml.
Estonian: Ühekordse intravenoosse annuse 1 mg/kg manustamise järel oli algne plasmakontsentratsioon 1040 ng/ml.
English: The efficacy of maropitant in reduction of nausea was demonstrated in studies using a model (xylazine-induced nausea).
Estonian: Maropitandi efektiivsus iivelduse vähendamisel on tõendatud uuringutega, milles kasutati mudelit (ksülasiini indutseeritud iiveldus).
English: QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains:
Estonian: KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS 1 ml sisaldab: Toimeaine: Maropitant
English: The veterinary medicinal product solution for injection should be injected subcutaneously or intravenously, once daily, at a dose of 1 mg of maropitant / kg bodyweight (1 ml/10 kg bodyweight) for up to 5 consecutive days.
Estonian: Veterinaarravimi süstelahust tuleb süstida subkutaanselt või intravenoosselt üks kord ööpäevas annuses 1 mg maropitanti kehamassi kg kohta (1 ml 10 kg kehamassi kohta) kuni 5 järjestikusel päeval.
English: Plasma protein binding of maropitant in dogs is more than 99%.
Estonian: Koertel seondub maropitant enam kui 99% ulatuses plasmavalkudega.
English: Amber glass type I vial closed with a coated bromobutyl rubber stopper and aluminium cap in a cardboard box.
Estonian: Pappkarpi pakendatud merevaigukollasest klaasist I tüüpi viaal, mis on suletud kaetud bromobutüülkummist punnkorgiga ja alumiiniumkorgiga.
English: Apart from transient reactions at the injection site following subcutaneous administration, maropitant was well tolerated in dogs and young cats injected daily with up to 5 mg/kg (5 times the recommended dose) for 15 consecutive days (3-times the recommended duration of administration).
Estonian: Välja arvatud mööduvad süstekoha reaktsioonid subkutaansel manustamisel, oli maropitant koertel ja noortel kassidel, kellele manustati kuni 5 mg/kg (5 korda rohkem kui soovitatav annus) 15 järjestikusel päeval (3 korda kauem kui soovitatav manustamiskestus), hästi talutav.
English: TARGET SPECIES Dogs, cats
Estonian: LOOMALIIGID Koerad, kassid
English: Peak concentrations were followed by a decline in systemic exposure with an apparent elimination half-life (t1/2) of 8.84 hours.
Estonian: Tippkontsentratsioonile järgnes süsteemse ekspositsiooni vähenemine, kusjuures näiline eliminatsiooni poolväärtusaeg (t1/2) oli 8,84 tundi.
English: The use of the veterinary medicinal product against vomiting due to motion sickness is not recommended.
Estonian: Seda veterinaarravimit ei soovitata kasutada kinetoosist tingitud oksendamise vastu.
English: STATEMENT OF ACTIVE SUBSTANCES 10 mg/ml maropitant
Estonian: TOIMEAINE(TE) SISALDUS 10 mg/ml maropitant
English: Peak concentrations were followed by a decline in systemic exposure with an apparent elimination half-life (t1/2) of 16.8 hours.
Estonian: Tippkontsentratsioonile järgnes süsteemse ekspositsiooni vähenemine, kusjuures näiline eliminatsiooni poolväärtusaeg (t1/2) oli 16,8 tundi.